Axicabtagene Ciloleucel Drug Asset Due Diligence Report 2026

This Axicabtagene Ciloleucel Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

333

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Axicabtagene Ciloleucel can convert its Autologous CAR-T profile and CD19 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Axicabtagene Ciloleucel (query alias: axicabtagene)
Modality / target	Autologous CAR-T; CD19; CD19 modulators
Highest global status	Approved
Originator	Kite Pharma, Inc.
Active developers	Kite Pharma, Inc., Gilead Sciences, Inc., Kite Pharma EU BV

The MCP disease footprint includes Primary mediastinal large B-cell lymphoma refractory, High grade B-cell lymphoma, Recurrent Follicular Lymphoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07479797	Phase 3	Recruiting	550	Proportion of Participants in Complete Response (CR) at Month 6
NCT07538635	Phase 2	Recruiting	20	1-year PFS rate
NCT07606937	Early Phase 1	Recruiting	12	Objective response rate (ORR)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Acalabrutinib in Combination With Anti-CD19 Chimeric Antigen Receptor T-Cells (CART) in B-Cell Lymphoma

Phase 1/2; n=23; evaluation: not stated. Reported fields: -; Incidence of Adverse Events = 9 Participants ; -

Long-term real-world outcomes of axicabtagene ciloleucel (axi-cel) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL).

Not Applicable; n=1446; evaluation: Positive. Reported fields: DoR(5-year) = 38.0 %

Real-world outcomes of axicabtagene ciloleucel in older versus younger adults with diffuse large B-cell lymphoma.

Not Applicable; n=818; evaluation: Positive. Reported fields: ARF(30-day) = 6.2 % ; ARF(30-day) = 5.7 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Axicabtagene Ciloleucel addresses Primary mediastinal large B-cell lymphoma refractory, High grade B-cell lymphoma, Recurrent Follicular Lymphoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Autologous CAR-T—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 5 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2026-06-02	Cencora to Support U.S. Distribution of Kite’s CAR T-Cell Therapies	Approved	Financial terms not disclosed
2019-12-11	Kite And Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination Of Yescarta® And Mavrilimumab In Relapsed Or Refractory Large B-Cell Lymphoma	Approved	Financial terms not disclosed
2017-08-28	Gilead completes $11.9bn Kite acquisition	NDA/BLA	US$11,900.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO